Coherus BioSciences to Report Second Quarter 2022 Financial Results on August 4th, 2022
28 juil. 2022 16h01 HE
|
Coherus BioSciences, Inc.
REDWOOD CITY, Calif., July 28, 2022 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS), today announced that its second quarter 2022 financial results will be released after...
Coherus and Junshi Biosciences Announce FDA Acceptance of Resubmission of BLA for Toripalimab for the Treatment of Nasopharyngeal Carcinoma
06 juil. 2022 08h00 HE
|
Coherus BioSciences, Inc.
- FDA has set a target action date of December 23, 2022 for the toripalimab BLA - - Toripalimab will be the first and only immuno-oncology agent for NPC in U.S., if approved - REDWOOD CITY,...
Coherus and Junshi Biosciences Receive Complete Response Letter from U.S. FDA for Toripalimab BLA
02 mai 2022 07h00 HE
|
Coherus BioSciences, Inc.
- The CRL requests a quality process change Coherus and Junshi believe is readily addressable - - BLA resubmission anticipated by mid-summer 2022 with expected six month FDA review timeline - -...
Coherus and Junshi Biosciences Announce PD-1 Inhibitor Toripalimab Granted Orphan Drug Designation for Small Cell Lung Cancer in the United States
14 avr. 2022 08h30 HE
|
Coherus BioSciences, Inc.
REDWOOD CITY, Calif., and SHANGHAI, China, April 14, 2022 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS) and Shanghai Junshi Biosciences Co., Ltd. (“Junshi Biosciences”,...
Coherus and Junshi Biosciences Present Results of Phase 3 Study of Toripalimab in First Line Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma at 2022 AACR Annual Meeting
08 avr. 2022 13h10 HE
|
Coherus BioSciences, Inc.
SHANGHAI, China, and REDWOOD CITY, Calif., April 08, 2022 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (“Junshi Biosciences”, HKEX: 1877; SSE: 688180) and Coherus BioSciences, Inc....
Coherus Highlights Anticipated New Product Launches and Immuno-oncology Growth Strategy at Analyst Day Event
29 mars 2022 09h15 HE
|
Coherus BioSciences, Inc.
— Multiple near-term anticipated product launches and development of innovative immuno-oncology pipeline position Coherus for long-term growth – — Introducing 2026 revenue target of $1.2...
Coherus BioSciences Appoints Rosh Dias, MD, MRCP, Chief Medical Officer
15 mars 2022 08h00 HE
|
Coherus BioSciences, Inc.
REDWOOD CITY, Calif., March 15, 2022 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Nasdaq: “CHRS”, “the Company”, “Coherus”) today announced Rosh Dias, MD, MRCP, has been appointed Chief Medical...
Junshi Biosciences and Coherus Announce Presentation of Positive Results from CHOICE-01, a Phase 3 Clinical Trial Evaluating Toripalimab in Combination with Chemotherapy as First-Line Treatment for Non-Small Cell Lung Cancer, at March ASCO Plenary Series
15 mars 2022 07h30 HE
|
Coherus BioSciences, Inc.
– Toripalimab plus chemotherapy met both primary endpoint of progression free survival and prespecified secondary endpoint of overall survival compared to chemotherapy alone – - Data support the use...
Coherus and Junshi Biosciences Announce Positive Results from Phase 3 Esophageal Cancer Study of Toripalimab Published in Cancer Cell
04 mars 2022 08h00 HE
|
Coherus BioSciences, Inc.
- Toripalimab plus chemotherapy demonstrates improvement in co-primary endpoints of PFS and OS in patients with advanced ESCC - - PFS and OS benefits were observed across all PD-L1 expression...
Coherus and Junshi Biosciences Expand Immuno-Oncology Collaboration to Include TIGIT-Targeted Antibody
10 janv. 2022 07h30 HE
|
Coherus BioSciences, Inc.
• Coherus and Junshi Biosciences plan to evaluate the toripalimab + JS006 combinationin clinical trials in multiple tumor types • Combinations of PD-1 + TIGIT inhibitors have potential to expand...